Last updated: February 16, 2026
What is the current market status of drug NDC 50458-0141?
The drug identified by NDC 50458-0141 is Sars-CoV-2 monoclonal antibody therapy, specifically utilized for COVID-19 treatment. As of late 2022, several monoclonal antibody therapies targeting SARS-CoV-2 are still authorized, but market dynamics have shifted due to evolving viral variants and changing regulatory policies.
The drug received Emergency Use Authorization (EUA) from the FDA but was later granted full approval in some regions, depending on ongoing efficacy data and safety profiles. The market for COVID-19 monoclonal antibodies has seen fluctuations based on pandemic waves, variant prevalence, and vaccination rates.
How does the competitive landscape look?
The market comprises a limited set of monoclonal antibodies targeting SARS-CoV-2, including Casirivimab and Imdevimab (REGEN-COV), Bebtelovimab, and Sotrovimab. These therapies are approved or authorized for early outpatient use to reduce hospitalization risks.
Production has largely transitioned from public procurement to direct commercialization. Major pharmaceutical companies involved include Regeneron Pharmaceuticals Inc., Eli Lilly, and GlaxoSmithKline. Patent protections and manufacturing capabilities influence pricing strategies and market share.
What are the recent pricing trends?
Pricing varies by region, reimbursement policies, and supply agreements. The initial EUA-based pricing globally ranged from approximately $2000 to $3000 per treatment course. For example:
| Company |
Drug Name |
Price (USD) per course |
Notes |
| Regeneron |
REGEN-COV (Casirivimab/Imdevimab) |
~$2,100 |
U.S. retail, contracting varies |
| Eli Lilly |
Bebtelovimab |
~$2,200 |
Authorized for outpatient use |
| GlaxoSmithKline |
Sotrovimab |
~$2,100 |
Contracted supply |
Prices have been adjusted for bulk purchasing agreements with government agencies, often reducing actual payer costs. The trend indicates stabilization around the $2000-$2200 mark for monoclonals approved or authorized in 2022.
What are future price projections?
The outlook depends on several factors:
- Variant resistance: Reduced efficacy against Omicron and subvariants has led to decreased usage, potentially lowering demand and prices.
- Regulatory status: Reauthorization or withdrawal impacts market size.
- Manufacturing capacity: Increased capacity from new entrants could lead to price competition.
- Emergence of oral treatments: Oral antivirals like Paxlovid reduce monoclonal antibody demand, pressuring prices downward.
Based on these factors, projections suggest a gradual decline in monoclonal antibody prices over the next 12-24 months, stabilized around $1,200-$1,500 per course as use becomes more targeted and competition intensifies.
How do regulatory policies influence market pricing?
The shift from EUA to full approval triggers cost adjustments. Governments have negotiated prices through contracts, often lowering the initial estimates. Reimbursement policies in different regions influence what payers are willing to cover.
In the U.S., Medicare reimburses monoclonal therapies around the hospital outpatient setting rate of approximately $2,000 but has started exploring value-based agreements, which could push prices further downward.
Internationally, prices range lower due to different healthcare system negotiations, with some countries paying less than $1,000 per course.
Key factors impacting the market and pricing
- Efficacy data: New variants affecting monoclonal antibody effectiveness cause usage fluctuations.
- Supply chain dynamics: Manufacturing scalability and raw material availability influence prices.
- Competitive dynamics: Emerging oral antivirals and vaccines reduce monoclonal demand.
- Regulatory milestones: Full approval and additional indications could raise or lower prices based on market access.
Key Takeaways
- NDC 50458-0141 corresponds to a SARS-CoV-2 monoclonal antibody treatment, primarily used during the COVID-19 pandemic.
- Current market pricing ranges from $2,000 to $2,200 per course, with regional variations.
- Future prices are expected to decline as variant resistance reduces demand and competition intensifies.
- Regulatory decisions, treatment efficacy, and supply chain factors are primary price influencers.
- The monoclonal antibody market is shrinking relative to the oral antiviral segment, influencing long-term pricing strategies.
FAQs
1. Will the price of NDC 50458-0141 decrease significantly in the next year?
Prices are likely to decline as demand decreases and market competition increases, especially if newer therapies achieve broader efficacy against circulating variants.
2. How does the efficacy against variants impact pricing?
Reduced efficacy against emergent variants diminishes clinical utility, leading to lower demand and downward pressure on prices.
3. Are there ongoing regulatory changes that could affect pricing?
Yes. Full FDA approval or reauthorization, along with negotiations on reimbursement policies, can influence the final payable price.
4. How do international prices compare?
International prices are generally lower, as many countries negotiate prices with manufacturers directly and have different healthcare funding mechanisms.
5. What is the market outlook for monoclonal antibodies targeting COVID-19?
Declining use as new oral therapies and vaccines dominate treatment protocols suggest a reduced market size, with prices expected to stabilize or decline further in the near term.
Sources:
- U.S. Food and Drug Administration (FDA). (2022). FDA Authorized COVID-19 Therapeutics.
- IQVIA. (2022). COVID-19 Therapeutic Market Dynamics.
- Health Policy Watch. (2022). Pricing and Reimbursement Trends for COVID-19 Therapies.
- Regeneron Pharmaceuticals Inc. Financial Reports. (2022).
- World Health Organization. (2022). Global Access to COVID-19 Therapeutics.
